AND017 vs Roxadustat

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: HIF prolyl hydroxylase (HIF-PH1/2/3) · full Chronic Kidney Disease pipeline

AND017

Developed by Kind Pharmaceuticals

Phase 3 in Chronic Kidney Diseasesmall molecule
Partial signal

NCT05265325 · Phase 2 · completed

The study was randomized, triple-blind, and active-controlled, with 175 participants assigned to AND017 or standard erythropoiesis-stimulating therapy. However, the registry does not report whether the primary endpoints—adverse-event incidence and mean hemoglobin change at Week 6—were met, so the findings cannot be judged as demonstrating a positive effect.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: February 2027 · NCT07494409 (registry estimate)

No aligned efficacy figure on record for this race.

Roxadustat · Evrenzo

Marketed by Kyntra Bio and partners

Phase 3 in Chronic Kidney Diseasesmall molecule
Reliable signal

NCT01750190 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled Phase 3 trial in 922 non-dialysis CKD patients with anemia. The two primary efficacy endpoints—mean change in hemoglobin over weeks 28-52 and hemoglobin response during the first 24 weeks—were both statistically significant and strongly favored roxadustat over placebo (p<0.0001 for both). The study was adequately powered and used a hard hemoglobin-based clinical endpoint, supporting a strong design and result.

Next expected readout: October 2027 · NCT05970172 (registry estimate)

Reported efficacy

United States (US FDA) Submission: Mean Change From Baseline in Hb (g/dL) Over Weeks 28 to 52 Regardless of Rescue Therapy (Baseline (Day 1, Week 0), Weeks 28 to 52); Ex-US Submission: Number (%) of Participants Who Achieved a Hb Response During the First 24-Weeks of Treatment Censoring for Rescue Therapy (Baseline up to Week 24): Mean hemoglobin change over Weeks 28-52: 2.00 g/dL roxadustat vs 0.16 g/dL placebo; least-squares mean difference 1.85 g/dL (95% CI 1.735-1.967; p<0.0001). Hemoglobin response during the first 24 weeks: 523/608 roxadustat vs 20/305 placebo; odds ratio 77.56 (95% CI 44.73-134.48; p<0.0001). (met)

Result source: NCT01750190

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAND017Roxadustat
Kidney composite outcome—Trial running · NCT07487727—Trial running · NCT05970172
UACR, % change—Trial running · NCT07487727—Trial running · NCT05970172
eGFR slope—Trial running · NCT07487727-2.6 vs -3.2+0.6 vs placebon 389NCT01887600
Haemoglobin, change—Trial running · NCT074877272 vs 0.2+1.8 vs placebowk 52 · n 616NCT01750190
169 other results
  • 1.8 vs 0.4 wk 52 · n 1334 · Phase 3 · primary NCT02174627
  • 2.0 vs 0.3 n 312 · Phase 3 · primary NCT01887600
  • 2.6 vs 2.4 wk 52 · n 522 · Phase 3 · primary NCT02052310
  • 0.4 vs -0.1 wk 52 · n 370 · Phase 3 · primary NCT02273726
  • 0.4 vs 0.2 wk 52 · n 413 · Phase 3 · primary NCT02278341
  • 0.4 vs 0.2 wk 36 · n 354 · Phase 3 · primary NCT02278341
  • 0.8 vs 0.7 n 1003 · Phase 3 · primary NCT02174731
  • 0.5 vs -0.0 wk 36 · n 303 · Phase 3 · primary NCT02273726
  • 1.9 vs 0.5 wk 104 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.3 wk 100 · n 389 · Phase 3 · secondary NCT01887600
  • 1.7 vs 0.1 wk 96 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.4 wk 92 · n 389 · Phase 3 · secondary NCT01887600
  • 1.6 vs 0.4 wk 88 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.5 wk 84 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.3 wk 80 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.7 wk 76 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.3 wk 72 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.4 wk 68 · n 389 · Phase 3 · secondary NCT01887600
  • 1.6 vs 0.2 wk 64 · n 389 · Phase 3 · secondary NCT01887600
  • 2.0 vs 0.4 wk 60 · n 389 · Phase 3 · secondary NCT01887600
  • 1.7 vs 0.1 wk 56 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.3 wk 52 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.6 wk 52 · n 213 · Phase 3 · secondary NCT02174627
  • 2.0 vs 0.3 wk 44 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.2 wk 40 · n 389 · Phase 3 · secondary NCT01887600
  • 2.0 vs 0.2 wk 36 · n 608 · Phase 3 · secondary NCT01750190
  • 2.0 vs 0.2 wk 52 · n 156 · Phase 3 · secondary NCT01750190
  • 1.7 vs 0.2 wk 48 · n 389 · Phase 3 · secondary NCT01887600
  • 2.1 vs 0.4 wk 36 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.3 wk 32 · n 389 · Phase 3 · secondary NCT01887600
  • 2.0 vs 0.4 wk 28 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.4 wk 24 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.2 wk 22 · n 389 · Phase 3 · secondary NCT01887600
  • 2.2 vs 0.4 wk 20 · n 389 · Phase 3 · secondary NCT01887600
  • 2.1 vs 0.2 wk 18 · n 389 · Phase 3 · secondary NCT01887600
  • 2.4 vs 0.4 wk 16 · n 389 · Phase 3 · secondary NCT01887600
  • 2.2 vs 0.2 wk 14 · n 389 · Phase 3 · secondary NCT01887600
  • 2.4 vs 0.3 wk 12 · n 389 · Phase 3 · secondary NCT01887600
  • 2.1 vs 0.2 wk 10 · n 389 · Phase 3 · secondary NCT01887600
  • 2.2 vs 0.2 wk 8 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.1 wk 6 · n 389 · Phase 3 · secondary NCT01887600
  • 1.6 vs 0.1 wk 4 · n 389 · Phase 3 · secondary NCT01887600
  • 1.0 vs 0.0 wk 2 · n 389 · Phase 3 · secondary NCT01887600
  • 0.4 vs -0.0 wk 1 · n 389 · Phase 3 · secondary NCT01887600
  • 2.1 vs 0.5 n 311 · Phase 3 · secondary NCT01887600
  • 2.0 vs 0.4 n 312 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.3 n 291 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.3 n 124 · Phase 3 · secondary NCT01887600
  • 0.2 vs 0.1 wk 104 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 100 · n 413 · Phase 3 · secondary NCT02278341
  • 0.1 vs -0.1 wk 96 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.2 wk 92 · n 413 · Phase 3 · secondary NCT02278341
  • 0.0 vs -0.0 wk 88 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 84 · n 413 · Phase 3 · secondary NCT02278341
  • 0.1 vs -0.0 wk 80 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.2 wk 76 · n 413 · Phase 3 · secondary NCT02278341
  • 0.1 vs -0.0 wk 72 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 68 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs -0.1 wk 64 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.2 wk 60 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 56 · n 413 · Phase 3 · secondary NCT02278341
  • 2.6 vs 2.4 wk 52 · n 490 · Phase 3 · secondary NCT02052310
  • 0.4 vs 0.2 wk 52 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 48 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.3 wk 44 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 40 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.2 wk 36 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.1 wk 34 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 32 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 30 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.3 wk 28 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 26 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 24 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 22 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.2 wk 20 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.0 wk 18 · n 413 · Phase 3 · secondary NCT02278341
  • 0.6 vs 0.2 wk 16 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.0 wk 14 · n 413 · Phase 3 · secondary NCT02278341
  • 0.7 vs 0.1 wk 12 · n 413 · Phase 3 · secondary NCT02278341
  • 0.6 vs -0.0 wk 10 · n 413 · Phase 3 · secondary NCT02278341
  • 0.8 vs 0.1 wk 8 · n 413 · Phase 3 · secondary NCT02278341
  • 0.7 vs -0.0 wk 7 · n 413 · Phase 3 · secondary NCT02278341
  • 0.9 vs 0.1 wk 6 · n 413 · Phase 3 · secondary NCT02278341
  • 0.7 vs -0.0 wk 5 · n 413 · Phase 3 · secondary NCT02278341
  • 0.8 vs 0.1 wk 4 · n 413 · Phase 3 · secondary NCT02278341
  • 0.6 vs 0.1 wk 3 · n 413 · Phase 3 · secondary NCT02278341
  • 0.9 vs 0.7 n 836 · Phase 3 · secondary NCT02174731
  • 2.3 vs 2.5 wk 24 · n 228 · Phase 3 · secondary NCT02052310
  • 0.6 vs -0.0 wk 24 · n 189 · Phase 3 · secondary NCT02273726
  • 0.5 vs 0.1 wk 2 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 1 · n 413 · Phase 3 · secondary NCT02278341
  • 0.8 vs 0.6 n 280 · Phase 3 · secondary NCT02174731
  • 2.7 vs 2.5 n 435 · Phase 3 · secondary NCT02052310
  • 1.2 vs 0.0 2.0 mg/kg BIW · wk 8 · n 9 · Phase 2 · primary NCT00761657
  • 1.5 vs 0.0 2.0 mg/kg TIW · wk 8 · n 11 · Phase 2 · primary NCT00761657
  • 0.8 vs 0.0 1.5 mg/kg BIW · wk 8 · n 10 · Phase 2 · primary NCT00761657
  • 1.3 vs 0.0 1.5 mg/kg TIW · wk 8 · n 11 · Phase 2 · primary NCT00761657
  • 0.5 vs 0.0 1.0 mg/kg BIW · wk 8 · n 5 · Phase 2 · primary NCT00761657
  • 0.1 vs 0.0 1.0 mg/kg TIW · wk 8 · n 5 · Phase 2 · primary NCT00761657
  • 0.6 vs 0.0 0.7 mg/kg BIW · wk 8 · n 10 · Phase 2 · primary NCT00761657
  • 0.2 vs 0.0 0.7 mg/kg TIW · wk 8 · n 12 · Phase 2 · primary NCT00761657
  • 0.7 vs -2.5 2.0 mg/kg TIW · wk 7 · n 9 · Phase 2 · secondary NCT01147666
  • -2.0 vs -2.4 2.0 mg/kg TIW · wk 12 · n 3 · Phase 2 · secondary NCT01147666
  • -0.4 vs -2.5 1.8 mg/kg TIW · wk 20 · n 6 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.5 1.8 mg/kg TIW · wk 20 · n 11 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 1.8 mg/kg TIW · wk 19 · n 6 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 1.8 mg/kg TIW · wk 19 · n 11 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 1.8 mg/kg TIW · wk 17 · n 6 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 1.8 mg/kg TIW · wk 17 · n 11 · Phase 2 · secondary NCT01147666
  • 0.5 vs -2.4 1.8 mg/kg TIW · wk 14 · n 6 · Phase 2 · secondary NCT01147666
  • -0.0 vs -2.4 1.8 mg/kg TIW · wk 14 · n 11 · Phase 2 · secondary NCT01147666
  • 0.3 vs -2.4 1.8 mg/kg TIW · wk 12 · n 6 · Phase 2 · secondary NCT01147666
  • 0.0 vs -2.4 1.8 mg/kg TIW · wk 12 · n 11 · Phase 2 · secondary NCT01147666
  • 0.6 vs -2.4 1.8 mg/kg TIW · wk 10 · n 6 · Phase 2 · secondary NCT01147666
  • 0.2 vs -2.4 1.8 mg/kg TIW · wk 10 · n 11 · Phase 2 · secondary NCT01147666
  • 0.5 vs -2.4 1.8 mg/kg TIW · wk 8 · n 6 · Phase 2 · secondary NCT01147666
  • 0.1 vs -2.4 1.8 mg/kg TIW · wk 8 · n 11 · Phase 2 · secondary NCT01147666
  • 0.3 vs -2.5 1.8 mg/kg TIW · wk 7 · n 11 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.5 1.8 mg/kg TIW · wk 7 · n 11 · Phase 2 · secondary NCT01147666
  • 0.9 vs -2.5 1.5 mg/kg TIW · wk 7 · n 10 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.5 1.3 mg/kg TIW · wk 20 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 1.3 mg/kg TIW · wk 19 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 1.3 mg/kg TIW · wk 17 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 1.3 mg/kg TIW · wk 14 · n 11 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 1.3 mg/kg TIW · wk 12 · n 11 · Phase 2 · secondary NCT01147666
  • -0.2 vs -2.4 1.3 mg/kg TIW · wk 10 · n 11 · Phase 2 · secondary NCT01147666
  • 0.0 vs -2.4 1.3 mg/kg TIW · wk 8 · n 11 · Phase 2 · secondary NCT01147666
  • -0.2 vs -2.5 1.3 mg/kg TIW · wk 7 · n 11 · Phase 2 · secondary NCT01147666
  • -0.4 vs -2.5 1.0 mg/kg TIW · wk 7 · n 9 · Phase 2 · secondary NCT01147666
  • -0.8 vs -2.5 Weight Tiered 70-100-150 mg · wk 20 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.5 Weight Tiered 70-120-200 mg · wk 20 · n 10 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.5 Weight Tiered 70-120-200 mg · wk 20 · n 10 · Phase 2 · secondary NCT01147666
  • -0.8 vs -2.4 Weight Tiered 70-100-150 mg · wk 19 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 19 · n 10 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 Weight Tiered 70-120-200 mg · wk 19 · n 10 · Phase 2 · secondary NCT01147666
  • -0.5 vs -2.4 Weight Tiered 70-100-150 mg · wk 17 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 17 · n 10 · Phase 2 · secondary NCT01147666
  • 0.0 vs -2.4 Weight Tiered 70-120-200 mg · wk 17 · n 10 · Phase 2 · secondary NCT01147666
  • -0.4 vs -2.4 Weight Tiered 70-100-150 mg · wk 14 · n 11 · Phase 2 · secondary NCT01147666
  • -0.2 vs -2.4 Weight Tiered 70-120-200 mg · wk 14 · n 10 · Phase 2 · secondary NCT01147666
  • 0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 14 · n 10 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.4 Weight Tiered 70-100-150 mg · wk 12 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 12 · n 10 · Phase 2 · secondary NCT01147666
  • 0.4 vs -2.4 Weight Tiered 70-120-200 mg · wk 12 · n 10 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.4 Weight Tiered 70-100-150 mg · wk 10 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 10 · n 10 · Phase 2 · secondary NCT01147666
  • 0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 10 · n 10 · Phase 2 · secondary NCT01147666
  • -0.5 vs -2.4 Weight Tiered 70-100-150 mg · wk 8 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 8 · n 10 · Phase 2 · secondary NCT01147666
  • 0.2 vs -2.4 Weight Tiered 70-120-200 mg · wk 8 · n 10 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.5 Weight Tiered 70-100-150 mg · wk 7 · n 11 · Phase 2 · secondary NCT01147666
  • -0.5 vs -2.5 Weight Tiered 70-120-200 mg · wk 7 · n 10 · Phase 2 · secondary NCT01147666
  • 0.2 vs -2.5 Weight Tiered 70-120-200 mg · wk 7 · n 10 · Phase 2 · secondary NCT01147666
  • 0.1 vs -2.5 2.0 mg/kg · wk 20 · n 2 · Phase 2 · secondary NCT01147666
  • -2.8 vs -2.5 2.0 mg/kg TIW · wk 20 · n 3 · Phase 2 · secondary NCT01147666
  • 0.1 vs -2.4 2.0 mg/kg · wk 19 · n 2 · Phase 2 · secondary NCT01147666
  • -3.0 vs -2.4 2.0 mg/kg TIW · wk 19 · n 3 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 2.0 mg/kg · wk 17 · n 2 · Phase 2 · secondary NCT01147666
  • -2.7 vs -2.4 2.0 mg/kg TIW · wk 17 · n 3 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 2.0 mg/kg · wk 14 · n 2 · Phase 2 · secondary NCT01147666
  • -2.3 vs -2.4 2.0 mg/kg TIW · wk 14 · n 3 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 2.0 mg/kg · wk 12 · n 2 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 2.0 mg/kg · wk 10 · n 2 · Phase 2 · secondary NCT01147666
  • -1.5 vs -2.4 2.0 mg/kg TIW · wk 10 · n 3 · Phase 2 · secondary NCT01147666
  • 0.1 vs -2.4 2.0 mg/kg · wk 8 · n 2 · Phase 2 · secondary NCT01147666
  • -0.9 vs -2.4 2.0 mg/kg TIW · wk 8 · n 3 · Phase 2 · secondary NCT01147666
  • 0 vs -2.5 2.0 mg/kg · wk 7 · n 2 · Phase 2 · secondary NCT01147666
  • -0.9 vs -2.5 2.0 mg/kg TIW · wk 7 · n 3 · Phase 2 · secondary NCT01147666
  • -2.6 vs -2.5 1.5 mg/kg TIW · wk 7 · n 1 · Phase 2 · secondary NCT01147666

Kidney composite outcome

AND017
—Trial running · NCT07487727
Roxadustat
—Trial running · NCT05970172

UACR, % change

AND017
—Trial running · NCT07487727
Roxadustat
—Trial running · NCT05970172

eGFR slope

AND017
—Trial running · NCT07487727
Roxadustat
-2.6 vs -3.2+0.6 vs placebon 389NCT01887600

Haemoglobin, change

AND017
—Trial running · NCT07487727
Roxadustat
2 vs 0.2+1.8 vs placebowk 52 · n 616NCT01750190
169 other results
  • 1.8 vs 0.4 wk 52 · n 1334 · Phase 3 · primary NCT02174627
  • 2.0 vs 0.3 n 312 · Phase 3 · primary NCT01887600
  • 2.6 vs 2.4 wk 52 · n 522 · Phase 3 · primary NCT02052310
  • 0.4 vs -0.1 wk 52 · n 370 · Phase 3 · primary NCT02273726
  • 0.4 vs 0.2 wk 52 · n 413 · Phase 3 · primary NCT02278341
  • 0.4 vs 0.2 wk 36 · n 354 · Phase 3 · primary NCT02278341
  • 0.8 vs 0.7 n 1003 · Phase 3 · primary NCT02174731
  • 0.5 vs -0.0 wk 36 · n 303 · Phase 3 · primary NCT02273726
  • 1.9 vs 0.5 wk 104 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.3 wk 100 · n 389 · Phase 3 · secondary NCT01887600
  • 1.7 vs 0.1 wk 96 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.4 wk 92 · n 389 · Phase 3 · secondary NCT01887600
  • 1.6 vs 0.4 wk 88 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.5 wk 84 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.3 wk 80 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.7 wk 76 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.3 wk 72 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.4 wk 68 · n 389 · Phase 3 · secondary NCT01887600
  • 1.6 vs 0.2 wk 64 · n 389 · Phase 3 · secondary NCT01887600
  • 2.0 vs 0.4 wk 60 · n 389 · Phase 3 · secondary NCT01887600
  • 1.7 vs 0.1 wk 56 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.3 wk 52 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.6 wk 52 · n 213 · Phase 3 · secondary NCT02174627
  • 2.0 vs 0.3 wk 44 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.2 wk 40 · n 389 · Phase 3 · secondary NCT01887600
  • 2.0 vs 0.2 wk 36 · n 608 · Phase 3 · secondary NCT01750190
  • 2.0 vs 0.2 wk 52 · n 156 · Phase 3 · secondary NCT01750190
  • 1.7 vs 0.2 wk 48 · n 389 · Phase 3 · secondary NCT01887600
  • 2.1 vs 0.4 wk 36 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.3 wk 32 · n 389 · Phase 3 · secondary NCT01887600
  • 2.0 vs 0.4 wk 28 · n 389 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.4 wk 24 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.2 wk 22 · n 389 · Phase 3 · secondary NCT01887600
  • 2.2 vs 0.4 wk 20 · n 389 · Phase 3 · secondary NCT01887600
  • 2.1 vs 0.2 wk 18 · n 389 · Phase 3 · secondary NCT01887600
  • 2.4 vs 0.4 wk 16 · n 389 · Phase 3 · secondary NCT01887600
  • 2.2 vs 0.2 wk 14 · n 389 · Phase 3 · secondary NCT01887600
  • 2.4 vs 0.3 wk 12 · n 389 · Phase 3 · secondary NCT01887600
  • 2.1 vs 0.2 wk 10 · n 389 · Phase 3 · secondary NCT01887600
  • 2.2 vs 0.2 wk 8 · n 389 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.1 wk 6 · n 389 · Phase 3 · secondary NCT01887600
  • 1.6 vs 0.1 wk 4 · n 389 · Phase 3 · secondary NCT01887600
  • 1.0 vs 0.0 wk 2 · n 389 · Phase 3 · secondary NCT01887600
  • 0.4 vs -0.0 wk 1 · n 389 · Phase 3 · secondary NCT01887600
  • 2.1 vs 0.5 n 311 · Phase 3 · secondary NCT01887600
  • 2.0 vs 0.4 n 312 · Phase 3 · secondary NCT01887600
  • 1.9 vs 0.3 n 291 · Phase 3 · secondary NCT01887600
  • 1.8 vs 0.3 n 124 · Phase 3 · secondary NCT01887600
  • 0.2 vs 0.1 wk 104 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 100 · n 413 · Phase 3 · secondary NCT02278341
  • 0.1 vs -0.1 wk 96 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.2 wk 92 · n 413 · Phase 3 · secondary NCT02278341
  • 0.0 vs -0.0 wk 88 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 84 · n 413 · Phase 3 · secondary NCT02278341
  • 0.1 vs -0.0 wk 80 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.2 wk 76 · n 413 · Phase 3 · secondary NCT02278341
  • 0.1 vs -0.0 wk 72 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 68 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs -0.1 wk 64 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.2 wk 60 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 56 · n 413 · Phase 3 · secondary NCT02278341
  • 2.6 vs 2.4 wk 52 · n 490 · Phase 3 · secondary NCT02052310
  • 0.4 vs 0.2 wk 52 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 48 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.3 wk 44 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 40 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.2 wk 36 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.1 wk 34 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 32 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 30 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.3 wk 28 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 26 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 24 · n 413 · Phase 3 · secondary NCT02278341
  • 0.3 vs 0.1 wk 22 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.2 wk 20 · n 413 · Phase 3 · secondary NCT02278341
  • 0.4 vs 0.0 wk 18 · n 413 · Phase 3 · secondary NCT02278341
  • 0.6 vs 0.2 wk 16 · n 413 · Phase 3 · secondary NCT02278341
  • 0.5 vs 0.0 wk 14 · n 413 · Phase 3 · secondary NCT02278341
  • 0.7 vs 0.1 wk 12 · n 413 · Phase 3 · secondary NCT02278341
  • 0.6 vs -0.0 wk 10 · n 413 · Phase 3 · secondary NCT02278341
  • 0.8 vs 0.1 wk 8 · n 413 · Phase 3 · secondary NCT02278341
  • 0.7 vs -0.0 wk 7 · n 413 · Phase 3 · secondary NCT02278341
  • 0.9 vs 0.1 wk 6 · n 413 · Phase 3 · secondary NCT02278341
  • 0.7 vs -0.0 wk 5 · n 413 · Phase 3 · secondary NCT02278341
  • 0.8 vs 0.1 wk 4 · n 413 · Phase 3 · secondary NCT02278341
  • 0.6 vs 0.1 wk 3 · n 413 · Phase 3 · secondary NCT02278341
  • 0.9 vs 0.7 n 836 · Phase 3 · secondary NCT02174731
  • 2.3 vs 2.5 wk 24 · n 228 · Phase 3 · secondary NCT02052310
  • 0.6 vs -0.0 wk 24 · n 189 · Phase 3 · secondary NCT02273726
  • 0.5 vs 0.1 wk 2 · n 413 · Phase 3 · secondary NCT02278341
  • 0.2 vs 0.1 wk 1 · n 413 · Phase 3 · secondary NCT02278341
  • 0.8 vs 0.6 n 280 · Phase 3 · secondary NCT02174731
  • 2.7 vs 2.5 n 435 · Phase 3 · secondary NCT02052310
  • 1.2 vs 0.0 2.0 mg/kg BIW · wk 8 · n 9 · Phase 2 · primary NCT00761657
  • 1.5 vs 0.0 2.0 mg/kg TIW · wk 8 · n 11 · Phase 2 · primary NCT00761657
  • 0.8 vs 0.0 1.5 mg/kg BIW · wk 8 · n 10 · Phase 2 · primary NCT00761657
  • 1.3 vs 0.0 1.5 mg/kg TIW · wk 8 · n 11 · Phase 2 · primary NCT00761657
  • 0.5 vs 0.0 1.0 mg/kg BIW · wk 8 · n 5 · Phase 2 · primary NCT00761657
  • 0.1 vs 0.0 1.0 mg/kg TIW · wk 8 · n 5 · Phase 2 · primary NCT00761657
  • 0.6 vs 0.0 0.7 mg/kg BIW · wk 8 · n 10 · Phase 2 · primary NCT00761657
  • 0.2 vs 0.0 0.7 mg/kg TIW · wk 8 · n 12 · Phase 2 · primary NCT00761657
  • 0.7 vs -2.5 2.0 mg/kg TIW · wk 7 · n 9 · Phase 2 · secondary NCT01147666
  • -2.0 vs -2.4 2.0 mg/kg TIW · wk 12 · n 3 · Phase 2 · secondary NCT01147666
  • -0.4 vs -2.5 1.8 mg/kg TIW · wk 20 · n 6 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.5 1.8 mg/kg TIW · wk 20 · n 11 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 1.8 mg/kg TIW · wk 19 · n 6 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 1.8 mg/kg TIW · wk 19 · n 11 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 1.8 mg/kg TIW · wk 17 · n 6 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 1.8 mg/kg TIW · wk 17 · n 11 · Phase 2 · secondary NCT01147666
  • 0.5 vs -2.4 1.8 mg/kg TIW · wk 14 · n 6 · Phase 2 · secondary NCT01147666
  • -0.0 vs -2.4 1.8 mg/kg TIW · wk 14 · n 11 · Phase 2 · secondary NCT01147666
  • 0.3 vs -2.4 1.8 mg/kg TIW · wk 12 · n 6 · Phase 2 · secondary NCT01147666
  • 0.0 vs -2.4 1.8 mg/kg TIW · wk 12 · n 11 · Phase 2 · secondary NCT01147666
  • 0.6 vs -2.4 1.8 mg/kg TIW · wk 10 · n 6 · Phase 2 · secondary NCT01147666
  • 0.2 vs -2.4 1.8 mg/kg TIW · wk 10 · n 11 · Phase 2 · secondary NCT01147666
  • 0.5 vs -2.4 1.8 mg/kg TIW · wk 8 · n 6 · Phase 2 · secondary NCT01147666
  • 0.1 vs -2.4 1.8 mg/kg TIW · wk 8 · n 11 · Phase 2 · secondary NCT01147666
  • 0.3 vs -2.5 1.8 mg/kg TIW · wk 7 · n 11 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.5 1.8 mg/kg TIW · wk 7 · n 11 · Phase 2 · secondary NCT01147666
  • 0.9 vs -2.5 1.5 mg/kg TIW · wk 7 · n 10 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.5 1.3 mg/kg TIW · wk 20 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 1.3 mg/kg TIW · wk 19 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 1.3 mg/kg TIW · wk 17 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 1.3 mg/kg TIW · wk 14 · n 11 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 1.3 mg/kg TIW · wk 12 · n 11 · Phase 2 · secondary NCT01147666
  • -0.2 vs -2.4 1.3 mg/kg TIW · wk 10 · n 11 · Phase 2 · secondary NCT01147666
  • 0.0 vs -2.4 1.3 mg/kg TIW · wk 8 · n 11 · Phase 2 · secondary NCT01147666
  • -0.2 vs -2.5 1.3 mg/kg TIW · wk 7 · n 11 · Phase 2 · secondary NCT01147666
  • -0.4 vs -2.5 1.0 mg/kg TIW · wk 7 · n 9 · Phase 2 · secondary NCT01147666
  • -0.8 vs -2.5 Weight Tiered 70-100-150 mg · wk 20 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.5 Weight Tiered 70-120-200 mg · wk 20 · n 10 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.5 Weight Tiered 70-120-200 mg · wk 20 · n 10 · Phase 2 · secondary NCT01147666
  • -0.8 vs -2.4 Weight Tiered 70-100-150 mg · wk 19 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 19 · n 10 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 Weight Tiered 70-120-200 mg · wk 19 · n 10 · Phase 2 · secondary NCT01147666
  • -0.5 vs -2.4 Weight Tiered 70-100-150 mg · wk 17 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 17 · n 10 · Phase 2 · secondary NCT01147666
  • 0.0 vs -2.4 Weight Tiered 70-120-200 mg · wk 17 · n 10 · Phase 2 · secondary NCT01147666
  • -0.4 vs -2.4 Weight Tiered 70-100-150 mg · wk 14 · n 11 · Phase 2 · secondary NCT01147666
  • -0.2 vs -2.4 Weight Tiered 70-120-200 mg · wk 14 · n 10 · Phase 2 · secondary NCT01147666
  • 0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 14 · n 10 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.4 Weight Tiered 70-100-150 mg · wk 12 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 12 · n 10 · Phase 2 · secondary NCT01147666
  • 0.4 vs -2.4 Weight Tiered 70-120-200 mg · wk 12 · n 10 · Phase 2 · secondary NCT01147666
  • -0.6 vs -2.4 Weight Tiered 70-100-150 mg · wk 10 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 10 · n 10 · Phase 2 · secondary NCT01147666
  • 0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 10 · n 10 · Phase 2 · secondary NCT01147666
  • -0.5 vs -2.4 Weight Tiered 70-100-150 mg · wk 8 · n 11 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 Weight Tiered 70-120-200 mg · wk 8 · n 10 · Phase 2 · secondary NCT01147666
  • 0.2 vs -2.4 Weight Tiered 70-120-200 mg · wk 8 · n 10 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.5 Weight Tiered 70-100-150 mg · wk 7 · n 11 · Phase 2 · secondary NCT01147666
  • -0.5 vs -2.5 Weight Tiered 70-120-200 mg · wk 7 · n 10 · Phase 2 · secondary NCT01147666
  • 0.2 vs -2.5 Weight Tiered 70-120-200 mg · wk 7 · n 10 · Phase 2 · secondary NCT01147666
  • 0.1 vs -2.5 2.0 mg/kg · wk 20 · n 2 · Phase 2 · secondary NCT01147666
  • -2.8 vs -2.5 2.0 mg/kg TIW · wk 20 · n 3 · Phase 2 · secondary NCT01147666
  • 0.1 vs -2.4 2.0 mg/kg · wk 19 · n 2 · Phase 2 · secondary NCT01147666
  • -3.0 vs -2.4 2.0 mg/kg TIW · wk 19 · n 3 · Phase 2 · secondary NCT01147666
  • -0.3 vs -2.4 2.0 mg/kg · wk 17 · n 2 · Phase 2 · secondary NCT01147666
  • -2.7 vs -2.4 2.0 mg/kg TIW · wk 17 · n 3 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 2.0 mg/kg · wk 14 · n 2 · Phase 2 · secondary NCT01147666
  • -2.3 vs -2.4 2.0 mg/kg TIW · wk 14 · n 3 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 2.0 mg/kg · wk 12 · n 2 · Phase 2 · secondary NCT01147666
  • -0.1 vs -2.4 2.0 mg/kg · wk 10 · n 2 · Phase 2 · secondary NCT01147666
  • -1.5 vs -2.4 2.0 mg/kg TIW · wk 10 · n 3 · Phase 2 · secondary NCT01147666
  • 0.1 vs -2.4 2.0 mg/kg · wk 8 · n 2 · Phase 2 · secondary NCT01147666
  • -0.9 vs -2.4 2.0 mg/kg TIW · wk 8 · n 3 · Phase 2 · secondary NCT01147666
  • 0 vs -2.5 2.0 mg/kg · wk 7 · n 2 · Phase 2 · secondary NCT01147666
  • -0.9 vs -2.5 2.0 mg/kg TIW · wk 7 · n 3 · Phase 2 · secondary NCT01147666
  • -2.6 vs -2.5 1.5 mg/kg TIW · wk 7 · n 1 · Phase 2 · secondary NCT01147666
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

AND017: no structured comparison results are available for Chronic Kidney Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. AND017: 0 of 4 rows · Roxadustat: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricRoxadustat
Dropout rate
43.3%a
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 40 more results
22.6%
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
37.3%
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
7.7%
NCT04655027 · Phase 4 · registry result, not featured evidence
18.2%
NCT04410198 · Phase 3 · registry result, not featured evidence
26.5%
NCT03329196 · Phase 3 · registry result, not featured evidence
25.9%
NCT03439137 · Phase 3 · registry result, not featured evidence
14.3%
NCT03402386 · Phase 3 · registry result, not featured evidence
12.5%
NCT03461146 · Phase 3 · registry result, not featured evidence
6.1%
NCT02174627 · Phase 3 · registry result, not featured evidence
6.6%
NCT02174731 · Phase 3 · registry result, not featured evidence
41.2%
NCT02052310 · Phase 3 · registry result, not featured evidence
65.7%
NCT02273726 · Phase 3 · registry result, not featured evidence
28.4%
NCT02278341 · Phase 3 · registry result, not featured evidence
66.7%
NCT01630889 · Phase 2 · registry result, not featured evidence
8.3%2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%2.0 mg/kg
NCT01147666 · Phase 2 · registry result, not featured evidence
80%2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
16.7%1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
41.7%1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
16.7%1.5 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
50%1.5 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
25%1.3 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
16.7%1.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
20%Weight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
25%Weight Tiered 70-100-150 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
25%Weight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
4.2%100 mg TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
16%70 mg BIW Then QW
NCT01244763 · Phase 2 · registry result, not featured evidence
8.3%50 mg TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
12.5%Tiered, Weight Based Dosing TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
12.5%Tiered, Weight Based Dosing TIW Then BIW
NCT01244763 · Phase 2 · registry result, not featured evidence
12.5%Tiered, Weight Based Dosing BIW Then QW
NCT01244763 · Phase 2 · registry result, not featured evidence
100%2.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
50%2.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—1.5 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—1.5 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
33.3%1.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
60%1.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—0.7 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—0.7 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
7.6%a
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 40 more results
0.6%
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
5.4%
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
—
NCT04655027 · Phase 4 · registry result, not featured evidence
2%
NCT04410198 · Phase 3 · registry result, not featured evidence
6.6%
NCT03329196 · Phase 3 · registry result, not featured evidence
9.9%
NCT03439137 · Phase 3 · registry result, not featured evidence
7.1%
NCT03402386 · Phase 3 · registry result, not featured evidence
8.3%
NCT03461146 · Phase 3 · registry result, not featured evidence
—
NCT02174627 · Phase 3 · registry result, not featured evidence
—
NCT02174731 · Phase 3 · registry result, not featured evidence
5.6%
NCT02052310 · Phase 3 · registry result, not featured evidence
7.3%
NCT02273726 · Phase 3 · registry result, not featured evidence
0.7%
NCT02278341 · Phase 3 · registry result, not featured evidence
—
NCT01630889 · Phase 2 · registry result, not featured evidence
8.3%2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%2.0 mg/kg
NCT01147666 · Phase 2 · registry result, not featured evidence
20%2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
8.3%1.5 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%1.5 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%1.3 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
8.3%1.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%Weight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
0%Weight Tiered 70-100-150 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
0%Weight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
0%100 mg TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
4%70 mg BIW Then QW
NCT01244763 · Phase 2 · registry result, not featured evidence
0%50 mg TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
4.2%Tiered, Weight Based Dosing TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
0%Tiered, Weight Based Dosing TIW Then BIW
NCT01244763 · Phase 2 · registry result, not featured evidence
0%Tiered, Weight Based Dosing BIW Then QW
NCT01244763 · Phase 2 · registry result, not featured evidence
0%2.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0%2.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—1.5 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—1.5 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0%1.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
10%1.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—0.7 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
—0.7 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
Serious AEs
52.5%a
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 40 more results
64.7%
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
61.6%
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
0%
NCT04655027 · Phase 4 · registry result, not featured evidence
25.6%
NCT04410198 · Phase 3 · registry result, not featured evidence
27.8%
NCT03329196 · Phase 3 · registry result, not featured evidence
25.3%
NCT03439137 · Phase 3 · registry result, not featured evidence
28.6%
NCT03402386 · Phase 3 · registry result, not featured evidence
29.2%
NCT03461146 · Phase 3 · registry result, not featured evidence
57.4%
NCT02174627 · Phase 3 · registry result, not featured evidence
57.6%
NCT02174731 · Phase 3 · registry result, not featured evidence
44.8%
NCT02052310 · Phase 3 · registry result, not featured evidence
65.4%
NCT02273726 · Phase 3 · registry result, not featured evidence
50.7%
NCT02278341 · Phase 3 · registry result, not featured evidence
60%
NCT01630889 · Phase 2 · registry result, not featured evidence
0%2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%2.0 mg/kg
NCT01147666 · Phase 2 · registry result, not featured evidence
40%2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
33.3%1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
41.7%1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
25%1.5 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
50%1.5 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
25%1.3 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0%1.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
30%Weight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
41.7%Weight Tiered 70-100-150 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
25%Weight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
16.7%100 mg TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
40%70 mg BIW Then QW
NCT01244763 · Phase 2 · registry result, not featured evidence
16.7%50 mg TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
12.5%Tiered, Weight Based Dosing TIW
NCT01244763 · Phase 2 · registry result, not featured evidence
16.7%Tiered, Weight Based Dosing TIW Then BIW
NCT01244763 · Phase 2 · registry result, not featured evidence
41.7%Tiered, Weight Based Dosing BIW Then QW
NCT01244763 · Phase 2 · registry result, not featured evidence
0%2.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0%2.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0%1.5 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0%1.5 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0%1.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0%1.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0%0.7 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
30.8%0.7 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
constipation 16.9% (placebo 11.1%)
hyperkalemia 16% (placebo 12.5%)
viral upper respiratory tract infection 15.9% (placebo 13.1%)
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 40 more results
hypertension 28.8%
oedema peripheral 14.9%
nausea 10.8%
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
hypertension 21.7% (placebo 13.3%)
oedema peripheral 11.3% (placebo 10.3%)
viral upper respiratory tract infection 9.7% (placebo 4.4%)
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
abdominal infection 7.7%
back pain 7.7%
hyperkalaemia 7.7%
NCT04655027 · Phase 4 · registry result, not featured evidence
diarrhoea 7.4%
cough 5.9%
covid-19 5.4%
NCT04410198 · Phase 3 · registry result, not featured evidence
nasopharyngitis 24.5%
diarrhoea 11.9%
constipation 9.3%
NCT03329196 · Phase 3 · registry result, not featured evidence
nasopharyngitis 45.7%
diarrhoea 15.4%
contusion 13%
NCT03439137 · Phase 3 · registry result, not featured evidence
catheter site infection 21.4%
diarrhoea 19%
nasopharyngitis 14.3%
NCT03402386 · Phase 3 · registry result, not featured evidence
nasopharyngitis 20.8%
shunt stenosis 20.8%
diarrhoea 16.7%
NCT03461146 · Phase 3 · registry result, not featured evidence
urinary tract infection 11% (placebo 6.8%)
hypertension 10.7% (placebo 8.5%)
oedema peripheral 10.4% (placebo 7.7%)
NCT02174627 · Phase 3 · registry result, not featured evidence
diarrhoea 10.9%
hypertension 8.1%
headache 7.5%
NCT02174731 · Phase 3 · registry result, not featured evidence
hypertension 18.4%
diarrhea 13.8%
muscle spasms 11.5%
NCT02052310 · Phase 3 · registry result, not featured evidence
nausea 17%
vomiting 16.2%
hypertension 15.9%
NCT02273726 · Phase 3 · registry result, not featured evidence
hypertension 15.9%
headache 8.7%
diarrhoea 8%
NCT02278341 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 40%
cough 33.3%
abdominal pain 20%
NCT01630889 · Phase 2 · registry result, not featured evidence
2.0 mg/kg TIW
nausea 8.3% (placebo 0%)
anaemia 0% (placebo 25%)
arteriovenous fistula site complication 0% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
2.0 mg/kg
anaemia 0% (placebo 25%)
arteriovenous fistula site complication 0% (placebo 0%)
catheter site pain 0% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
2.0 mg/kg TIW
cough 20% (placebo 0%)
fatigue 20% (placebo 0%)
haemoglobin decreased 20% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
1.8 mg/kg TIW
anaemia 16.7% (placebo 25%)
diarrhoea 16.7% (placebo 0%)
nausea 8.3% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
1.8 mg/kg TIW
diarrhoea 16.7% (placebo 0%)
anaemia 0% (placebo 25%)
arteriovenous fistula site complication 0% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
1.5 mg/kg TIW
diarrhoea 8.3% (placebo 0%)
anaemia 0% (placebo 25%)
arteriovenous fistula site complication 0% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
1.5 mg/kg TIW
anaemia 25% (placebo 25%)
arteriovenous fistula site complication 25% (placebo 0%)
catheter site pain 25% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
1.3 mg/kg TIW
diarrhoea 16.7% (placebo 0%)
anaemia 0% (placebo 25%)
arteriovenous fistula site complication 0% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
1.0 mg/kg TIW
nausea 25% (placebo 0%)
diarrhoea 8.3% (placebo 0%)
anaemia 0% (placebo 25%)
NCT01147666 · Phase 2 · registry result, not featured evidence
Weight Tiered 70-120-200 mg
anaemia 20% (placebo 25%)
nausea 10% (placebo 0%)
arteriovenous fistula site complication 0% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
Weight Tiered 70-100-150 mg
anaemia 8.3% (placebo 25%)
arteriovenous fistula site complication 0% (placebo 0%)
catheter site pain 0% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
Weight Tiered 70-120-200 mg
nausea 16.7% (placebo 0%)
anaemia 0% (placebo 25%)
arteriovenous fistula site complication 0% (placebo 0%)
NCT01147666 · Phase 2 · registry result, not featured evidence
100 mg TIW
nausea 12.5%
diarrhoea 8.3%
headache 8.3%
NCT01244763 · Phase 2 · registry result, not featured evidence
70 mg BIW Then QW
oedema peripheral 16%
urinary tract infection 12%
nasopharyngitis 8%
NCT01244763 · Phase 2 · registry result, not featured evidence
50 mg TIW
oedema peripheral 16.7%
dizziness 12.5%
diarrhoea 8.3%
NCT01244763 · Phase 2 · registry result, not featured evidence
Tiered, Weight Based Dosing TIW
hypertension 16.7%
nausea 16.7%
diarrhoea 12.5%
NCT01244763 · Phase 2 · registry result, not featured evidence
Tiered, Weight Based Dosing TIW Then BIW
oedema peripheral 20.8%
diarrhoea 16.7%
urinary tract infection 16.7%
NCT01244763 · Phase 2 · registry result, not featured evidence
Tiered, Weight Based Dosing BIW Then QW
nausea 20.8%
urinary tract infection 16.7%
constipation 12.5%
NCT01244763 · Phase 2 · registry result, not featured evidence
2.0 mg/kg BIW
fatigue 18.2% (placebo 0%)
back pain 9.1% (placebo 3.6%)
diarrhoea 9.1% (placebo 7.1%)
NCT00761657 · Phase 2 · registry result, not featured evidence
2.0 mg/kg TIW
allergic sinusitis 8.3% (placebo 0%)
benign breast neoplasm 8.3% (placebo 0%)
cystitis 8.3% (placebo 0%)
NCT00761657 · Phase 2 · registry result, not featured evidence
1.5 mg/kg BIW
headache 30% (placebo 3.6%)
hyperkalaemia 20% (placebo 0%)
back pain 10% (placebo 3.6%)
NCT00761657 · Phase 2 · registry result, not featured evidence
1.5 mg/kg TIW
hyperuricaemia 18.2% (placebo 0%)
renal impairment 18.2% (placebo 0%)
acidosis 9.1% (placebo 0%)
NCT00761657 · Phase 2 · registry result, not featured evidence
1.0 mg/kg BIW
diarrhoea 16.7% (placebo 7.1%)
anorexia 8.3% (placebo 0%)
chills 8.3% (placebo 0%)
NCT00761657 · Phase 2 · registry result, not featured evidence
1.0 mg/kg TIW
back pain 22.2% (placebo 3.6%)
prostatitis 16.7% (placebo 0%)
breast cyst 11.1% (placebo 0%)
NCT00761657 · Phase 2 · registry result, not featured evidence
0.7 mg/kg BIW
anaemia 10% (placebo 0%)
hyperkalaemia 10% (placebo 0%)
hypernatraemia 10% (placebo 0%)
NCT00761657 · Phase 2 · registry result, not featured evidence
0.7 mg/kg TIW
diarrhoea 23.1% (placebo 7.1%)
abdominal pain 7.7% (placebo 0%)
abdominal pain upper 7.7% (placebo 0%)
NCT00761657 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 38 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Roxadustat

Hemoglobin Change g/dL 0.71 vs -2.5 placebo g/dL @ 7wk2.0 mg/kg TIW
absolute change · g/dL
NCT01147666 · Phase 2 · registry result, not featured evidence
show 169 more results
0 vs -2.5 placebo g/dL @ 7wk2.0 mg/kg
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.89 vs -2.5 placebo g/dL @ 7wk2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0.05 vs -2.37 placebo g/dL @ 8wk2.0 mg/kg
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.89 vs -2.37 placebo g/dL @ 8wk2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.15 vs -2.37 placebo g/dL @ 10wk2.0 mg/kg
NCT01147666 · Phase 2 · registry result, not featured evidence
-1.46 vs -2.37 placebo g/dL @ 10wk2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.15 vs -2.37 placebo g/dL @ 12wk2.0 mg/kg
NCT01147666 · Phase 2 · registry result, not featured evidence
-2.02 vs -2.37 placebo g/dL @ 12wk2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.15 vs -2.37 placebo g/dL @ 14wk2.0 mg/kg
NCT01147666 · Phase 2 · registry result, not featured evidence
-2.29 vs -2.37 placebo g/dL @ 14wk2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.3 vs -2.37 placebo g/dL @ 17wk2.0 mg/kg
NCT01147666 · Phase 2 · registry result, not featured evidence
-2.69 vs -2.37 placebo g/dL @ 17wk2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0.05 vs -2.37 placebo g/dL @ 19wk2.0 mg/kg
NCT01147666 · Phase 2 · registry result, not featured evidence
-3.02 vs -2.37 placebo g/dL @ 19wk2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0.15 vs -2.47 placebo g/dL @ 20wk2.0 mg/kg
NCT01147666 · Phase 2 · registry result, not featured evidence
-2.82 vs -2.47 placebo g/dL @ 20wk2.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
1.21 vs 0.04 placebo g/dL @ 8wk2.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
1.52 vs 0.04 placebo g/dL @ 8wk2.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0.25 vs -2.5 placebo g/dL @ 7wk1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.15 vs -2.5 placebo g/dL @ 7wk1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0.49 vs -2.37 placebo g/dL @ 8wk1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0.08 vs -2.37 placebo g/dL @ 8wk1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0.56 vs -2.37 placebo g/dL @ 10wk1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0.17 vs -2.37 placebo g/dL @ 10wk1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0.26 vs -2.37 placebo g/dL @ 12wk1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0.04 vs -2.37 placebo g/dL @ 12wk1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0.53 vs -2.37 placebo g/dL @ 14wk1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.03 vs -2.37 placebo g/dL @ 14wk1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.09 vs -2.37 placebo g/dL @ 17wk1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.09 vs -2.37 placebo g/dL @ 17wk1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.11 vs -2.37 placebo g/dL @ 19wk1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.32 vs -2.37 placebo g/dL @ 19wk1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.39 vs -2.47 placebo g/dL @ 20wk1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.55 vs -2.47 placebo g/dL @ 20wk1.8 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0.91 vs -2.5 placebo g/dL @ 7wk1.5 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
-2.63 vs -2.5 placebo g/dL @ 7wk1.5 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0.79 vs 0.04 placebo g/dL @ 8wk1.5 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
1.31 vs 0.04 placebo g/dL @ 8wk1.5 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
-0.18 vs -2.5 placebo g/dL @ 7wk1.3 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0.01 vs -2.37 placebo g/dL @ 8wk1.3 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.17 vs -2.37 placebo g/dL @ 10wk1.3 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.1 vs -2.37 placebo g/dL @ 12wk1.3 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.27 vs -2.37 placebo g/dL @ 14wk1.3 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.27 vs -2.37 placebo g/dL @ 17wk1.3 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.28 vs -2.37 placebo g/dL @ 19wk1.3 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.55 vs -2.47 placebo g/dL @ 20wk1.3 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.4 vs -2.5 placebo g/dL @ 7wk1.0 mg/kg TIW
NCT01147666 · Phase 2 · registry result, not featured evidence
0.5 vs 0.04 placebo g/dL @ 8wk1.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0.05 vs 0.04 placebo g/dL @ 8wk1.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0.59 vs 0.04 placebo g/dL @ 8wk0.7 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence
0.24 vs 0.04 placebo g/dL @ 8wk0.7 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence
2 vs 0.16 placebo g/dL @ 52wk
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
2.02 vs 0.2 placebo g/dL @ 36wk
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
2.02 vs 0.18 placebo g/dL @ 52wk
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.992 vs 0.3 placebo g/dL
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
2.069 vs 0.47 placebo g/dL
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
0.39 vs -0.006 placebo g/dL @ 1wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
0.977 vs 0.039 placebo g/dL @ 2wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.591 vs 0.119 placebo g/dL @ 4wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.927 vs 0.1 placebo g/dL @ 6wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
2.236 vs 0.178 placebo g/dL @ 8wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
2.129 vs 0.18 placebo g/dL @ 10wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
2.412 vs 0.322 placebo g/dL @ 12wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
2.214 vs 0.163 placebo g/dL @ 14wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
2.365 vs 0.378 placebo g/dL @ 16wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
2.087 vs 0.246 placebo g/dL @ 18wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
2.191 vs 0.367 placebo g/dL @ 20wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.873 vs 0.222 placebo g/dL @ 22wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.802 vs 0.355 placebo g/dL @ 24wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.996 vs 0.435 placebo g/dL @ 28wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.911 vs 0.324 placebo g/dL @ 32wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
2.1 vs 0.41 placebo g/dL @ 36wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.887 vs 0.241 placebo g/dL @ 40wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.977 vs 0.278 placebo g/dL @ 44wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.695 vs 0.249 placebo g/dL @ 48wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.939 vs 0.298 placebo g/dL @ 52wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.725 vs 0.085 placebo g/dL @ 56wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.988 vs 0.354 placebo g/dL @ 60wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.637 vs 0.233 placebo g/dL @ 64wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.913 vs 0.414 placebo g/dL @ 68wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.765 vs 0.328 placebo g/dL @ 72wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.859 vs 0.674 placebo g/dL @ 76wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.752 vs 0.308 placebo g/dL @ 80wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.854 vs 0.48 placebo g/dL @ 84wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.57 vs 0.399 placebo g/dL @ 88wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.8 vs 0.418 placebo g/dL @ 92wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.701 vs 0.139 placebo g/dL @ 96wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.763 vs 0.315 placebo g/dL @ 100wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.857 vs 0.511 placebo g/dL @ 104wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
2.013 vs 0.399 placebo g/dL
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.886 vs 0.292 placebo g/dL
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.779 vs 0.327 placebo g/dL
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
1.75 vs 0.4 placebo g/dL @ 52wk
NCT02174627 · Phase 3 · registry result, not featured evidence
1.75 vs 0.62 placebo g/dL @ 52wk
NCT02174627 · Phase 3 · registry result, not featured evidence
0.77 vs 0.68 Epoetin Alfa g/dL
NCT02174731 · Phase 3 · registry result, not featured evidence
0.88 vs 0.74 Epoetin Alfa g/dL
NCT02174731 · Phase 3 · registry result, not featured evidence
0.8 vs 0.59 Epoetin Alfa g/dL
NCT02174731 · Phase 3 · registry result, not featured evidence
2.57 vs 2.36 Epoetin Alfa g/dL @ 52wk
NCT02052310 · Phase 3 · registry result, not featured evidence
2.62 vs 2.44 Epoetin Alfa g/dL @ 52wk
NCT02052310 · Phase 3 · registry result, not featured evidence
2.34 vs 2.48 Epoetin Alfa g/dL @ 24wk
NCT02052310 · Phase 3 · registry result, not featured evidence
2.7 vs 2.46 Epoetin Alfa g/dL
NCT02052310 · Phase 3 · registry result, not featured evidence
0.39 vs -0.09 Epoetin Alfa g/dL @ 52wk
NCT02273726 · Phase 3 · registry result, not featured evidence
0.54 vs -0.03 Epoetin Alfa g/dL @ 36wk
NCT02273726 · Phase 3 · registry result, not featured evidence
0.61 vs -0.03 Epoetin Alfa g/dL @ 24wk
NCT02273726 · Phase 3 · registry result, not featured evidence
0.428 vs 0.193 ESA g/dL @ 36wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.363 vs 0.192 ESA g/dL @ 52wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.232 vs 0.068 ESA g/dL @ 1wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.496 vs 0.054 ESA g/dL @ 2wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.633 vs 0.071 ESA g/dL @ 3wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.803 vs 0.095 ESA g/dL @ 4wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.723 vs -0.045 ESA g/dL @ 5wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.868 vs 0.138 ESA g/dL @ 6wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.698 vs -0.031 ESA g/dL @ 7wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.816 vs 0.116 ESA g/dL @ 8wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.64 vs -0.019 ESA g/dL @ 10wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.732 vs 0.139 ESA g/dL @ 12wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.508 vs 0.005 ESA g/dL @ 14wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.613 vs 0.244 ESA g/dL @ 16wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.38 vs 0.017 ESA g/dL @ 18wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.501 vs 0.217 ESA g/dL @ 20wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.266 vs 0.069 ESA g/dL @ 22wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.262 vs 0.075 ESA g/dL @ 24wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.316 vs 0.073 ESA g/dL @ 26wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.549 vs 0.342 ESA g/dL @ 28wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.333 vs 0.106 ESA g/dL @ 30wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.31 vs 0.111 ESA g/dL @ 32wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.364 vs 0.084 ESA g/dL @ 34wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.482 vs 0.225 ESA g/dL @ 36wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.199 vs 0.064 ESA g/dL @ 40wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.335 vs 0.252 ESA g/dL @ 44wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.158 vs 0.131 ESA g/dL @ 48wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.385 vs 0.186 ESA g/dL @ 52wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.217 vs 0.069 ESA g/dL @ 56wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.368 vs 0.171 ESA g/dL @ 60wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.181 vs -0.093 ESA g/dL @ 64wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.306 vs 0.1 ESA g/dL @ 68wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.109 vs -0.009 ESA g/dL @ 72wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.401 vs 0.189 ESA g/dL @ 76wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.087 vs -0.015 ESA g/dL @ 80wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.318 vs 0.126 ESA g/dL @ 84wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.026 vs -0.018 ESA g/dL @ 88wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.357 vs 0.154 ESA g/dL @ 92wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.126 vs -0.058 ESA g/dL @ 96wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.302 vs 0.138 ESA g/dL @ 100wk
NCT02278341 · Phase 3 · registry result, not featured evidence
0.232 vs 0.133 ESA g/dL @ 104wk
NCT02278341 · Phase 3 · registry result, not featured evidence
-0.32 vs -2.5 placebo g/dL @ 7wkWeight Tiered 70-100-150 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.47 vs -2.5 placebo g/dL @ 7wkWeight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
0.24 vs -2.5 placebo g/dL @ 7wkWeight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.49 vs -2.37 placebo g/dL @ 8wkWeight Tiered 70-100-150 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.29 vs -2.37 placebo g/dL @ 8wkWeight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
0.2 vs -2.37 placebo g/dL @ 8wkWeight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.56 vs -2.37 placebo g/dL @ 10wkWeight Tiered 70-100-150 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.27 vs -2.37 placebo g/dL @ 10wkWeight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
0.26 vs -2.37 placebo g/dL @ 10wkWeight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.56 vs -2.37 placebo g/dL @ 12wkWeight Tiered 70-100-150 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.35 vs -2.37 placebo g/dL @ 12wkWeight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
0.38 vs -2.37 placebo g/dL @ 12wkWeight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.41 vs -2.37 placebo g/dL @ 14wkWeight Tiered 70-100-150 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.24 vs -2.37 placebo g/dL @ 14wkWeight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
0.33 vs -2.37 placebo g/dL @ 14wkWeight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.48 vs -2.37 placebo g/dL @ 17wkWeight Tiered 70-100-150 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.27 vs -2.37 placebo g/dL @ 17wkWeight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
0.02 vs -2.37 placebo g/dL @ 17wkWeight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.82 vs -2.37 placebo g/dL @ 19wkWeight Tiered 70-100-150 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.35 vs -2.37 placebo g/dL @ 19wkWeight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.1 vs -2.37 placebo g/dL @ 19wkWeight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.82 vs -2.47 placebo g/dL @ 20wkWeight Tiered 70-100-150 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.33 vs -2.47 placebo g/dL @ 20wkWeight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
-0.57 vs -2.47 placebo g/dL @ 20wkWeight Tiered 70-120-200 mg
NCT01147666 · Phase 2 · registry result, not featured evidence
Hemoglobin 86% (n=608) vs 6.6% (n=305) placebo @ 24wk
responder rate · % of participants
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to % from 523 Participants as posted
show 5 more results
79.2% (n=389) vs 9.9% (n=203) placebo @ 24wk
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
88.2% (n=490) vs 84.4% (n=468) Epoetin Alfa @ 24wk
NCT02052310 · Phase 3 · registry result, not featured evidence
84.3% (n=522) vs 79.5% (n=521) Epoetin Alfa @ 24wk
NCT02052310 · Phase 3 · registry result, not featured evidence
84.2% (n=386) vs 82.4% (n=397) ESA @ 36wk
NCT02278341 · Phase 3 · registry result, not featured evidence
83.1% (n=413) vs 82.1% (n=420) ESA @ 36wk
NCT02278341 · Phase 3 · registry result, not featured evidence
Hemoglobin Ge 10 76.8% (n=608) vs 18.4% (n=305) placebo @ 36wk
event count · % of participants
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 · converted to % from 467 Participants as posted
LDL-C -18.48 vs 0.22 placebo mg/dL @ 28wk
absolute change · mg/dL
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 2 more results
-23.8 vs -5.39 Epoetin Alfa mg/dL @ 24wk
NCT02052310 · Phase 3 · registry result, not featured evidence
-13.7 vs 1.23 Epoetin Alfa mg/dL @ 28wk
NCT02273726 · Phase 3 · registry result, not featured evidence
eGFR Slope -2.89 vs -3.1 placebo mL @ 52wk
absolute change · mL
NCT01750190 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
Hb 100% (n=9) vs 26.1% (n=23) placebo @ 8wk2.0 mg/kg BIW
responder rate · % of participants
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 9 Participants as posted
show 18 more results
100% (n=11) vs 26.1% (n=23) placebo @ 8wk*2.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 11 Participants as posted
100% (n=9) vs 34.8% (n=23) placebo @ 16wk*2.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 9 Participants as posted
100% (n=11) vs 34.8% (n=23) placebo @ 16wk*2.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 11 Participants as posted
80% (n=10) vs 26.1% (n=23) placebo @ 8wk*1.5 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 8 Participants as posted
90.9% (n=11) vs 26.1% (n=23) placebo @ 8wk*1.5 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 10 Participants as posted
90% (n=10) vs 34.8% (n=23) placebo @ 16wk*1.5 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 9 Participants as posted
90.9% (n=11) vs 34.8% (n=23) placebo @ 16wk*1.5 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 10 Participants as posted
60% (n=5) vs 26.1% (n=23) placebo @ 8wk*1.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
40% (n=5) vs 26.1% (n=23) placebo @ 8wk*1.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 2 Participants as posted
60% (n=5) vs 34.8% (n=23) placebo @ 16wk*1.0 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
40% (n=5) vs 34.8% (n=23) placebo @ 16wk*1.0 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 2 Participants as posted
50% (n=10) vs 26.1% (n=23) placebo @ 8wk*0.7 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 5 Participants as posted
58.3% (n=12) vs 26.1% (n=23) placebo @ 8wk*0.7 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
70% (n=10) vs 34.8% (n=23) placebo @ 16wk*0.7 mg/kg BIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
58.3% (n=12) vs 34.8% (n=23) placebo @ 16wk*0.7 mg/kg TIW
NCT00761657 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
89.5% (n=286) vs 78% (n=273) Darbepoetin Alfa @ 24wk
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
77% (n=1371) vs 8.5% (n=1357) placebo @ 24wk
NCT02174627 · Phase 3 · registry result, not featured evidence
66.1% (n=369) vs 58.6% (n=370) Epoetin Alfa @ 52wk
NCT02273726 · Phase 3 · registry result, not featured evidence
Hb Change 1.848 vs 1.839 Darbepoetin Alfa g/dL @ 36wk
absolute change · g/dL
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 1 more result
1.718 vs 1.673 Darbepoetin Alfa g/dL @ 52wk
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
LDL-C -0.352 vs 0.049 Darbepoetin Alfa mmol/L @ 28wk
absolute change · mmol/L
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 3 more results
-0.38 vs -0.02 placebo mmol/L @ 24wk
NCT02174627 · Phase 3 · registry result, not featured evidence
-0.38 vs -0.05 Epoetin Alfa mmol/L @ 24wk
NCT02174731 · Phase 3 · registry result, not featured evidence
-0.459 vs -0.082 ESA mmol/L @ 28wk
NCT02278341 · Phase 3 · registry result, not featured evidence
SF-36 Physical Functioning 0.913 vs 2.062 Darbepoetin Alfa score @ 28wk
absolute change · score
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 3 more results
1.344 vs 0.632 placebo score
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
0.14 vs -0.39 placebo score @ 28wk
NCT02174627 · Phase 3 · registry result, not featured evidence
0.05 vs -0.155 ESA score @ 28wk
NCT02278341 · Phase 3 · registry result, not featured evidence
Time to Response 88.8% (n=322) vs 77.7% (n=292) Darbepoetin Alfa @ 24wk
responder rate · % of participants
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 1 more result
88.2% (n=322) vs 77.4% (n=292) Darbepoetin Alfa @ 24wk
NCT02021318 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
SF-36 Vitality 2.788 vs 1.661 placebo score
absolute change · score
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 2 more results
1.59 vs 1.15 placebo score @ 28wk
NCT02174627 · Phase 3 · registry result, not featured evidence
0.46 vs -0.396 ESA score @ 28wk
NCT02278341 · Phase 3 · registry result, not featured evidence
Arterial Pressure -0.814 vs -1.656 placebo mmHg
absolute change · mmHg
NCT01887600 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3
show 2 more results
-0.12 vs 1.15 Epoetin Alfa mmHg @ 12wk
NCT02052310 · Phase 3 · registry result, not featured evidence
0.46 vs 0.04 Epoetin Alfa mmHg @ 28wk
NCT02273726 · Phase 3 · registry result, not featured evidence

+ 62 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AND017's landscape · Roxadustat's landscape